What is CV Sciences?
Headquartered in San Diego, California, CV Sciences operates as a multifaceted enterprise with two primary business units. The Pharmaceutical Division is dedicated to the rigorous development of synthetically formulated cannabidiol-based medicines, with a clear focus on achieving U.S. Food and Drug Administration (FDA) approval for specific therapeutic indications. This high-stakes research is complemented by the Consumer Products Division, which leverages botanical expertise to deliver high-quality cannabidiol products to the wellness market.
Since its inception in 2010, the company has positioned itself at the intersection of biotechnology and consumer health. By balancing the long-term, capital-intensive nature of drug development with the immediate revenue-generating potential of its consumer goods, CV Sciences maintains a unique market position that appeals to investors focused on both innovation and commercial scalability.
How much funding has CV Sciences raised?
CV Sciences has raised a total of $15.1M across 4 funding rounds:
Debt
$2M
Debt
$2M
Other Financing Round
$10M
Debt
$1.1M
Debt (2016): $2M, investors not publicly disclosed
Debt (2020): $2M led by PPP
Other Financing Round (2020): $10M supported by Tumim Stone Capital
Debt (2021): $1.1M, investors not publicly disclosed
Key Investors in CV Sciences
Tumim Stone Capital
An investment firm focused on providing strategic capital and financial solutions to growth-oriented companies.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participating in the funding round to support the company's long-term strategic objectives.
What's next for CV Sciences?
Looking ahead, the strategic deployment of the $1.1M will likely prioritize the acceleration of clinical trials and the refinement of the company's proprietary synthetic cannabidiol formulations. As the regulatory environment for cannabinoid-based therapeutics continues to evolve, CV Sciences must navigate the stringent requirements of the FDA to transition its pipeline candidates into viable commercial assets.
Furthermore, the company is expected to optimize its consumer product supply chain to maintain its competitive edge in the wellness sector. The integration of these capital resources will be pivotal in sustaining the firm's research momentum while ensuring that its commercial operations remain robust. Investors will be closely monitoring the company's progress in achieving key clinical milestones, which remain the primary drivers of long-term shareholder value in the pharmaceutical space.
